

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Claims:**

1. (Currently amended) An immunogenic composition capable of eliciting an HCV-specific T cell response, the immunogenic composition comprising a first expression cassette comprising a polynucleotide sequence that encodes an HCV Core protein and a second expression cassette comprising a polynucleotide sequence that encodes at least one other HCV protein, wherein the first and second expression cassettes cause expression of the Core protein and the at least one other HCV protein within the same cell, wherein the first expression cassette encoding the Core protein is in a cis location downstream of the second expression cassette that encodes at least one of the other HCV proteins.
2. (Previously presented) An immunogenic composition of claim 1, wherein the sequence of the polynucleotide sequence encoding the Core protein has been mutated, wherein the mutation reduces expression of the Core protein upon the expression of said at least one other HCV protein.
3. (Previously presented) The immunogenic composition of claim 1, wherein polynucleotide encodes a Core protein that is truncated from the carboxy terminal end in a sufficient amount to reduce the inhibitory effect of Core protein upon the expression of other HCV proteins.
4. (Previously presented) The immunogenic composition of claim 3, wherein the polynucleotide encodes a mature form of HCV Core protein after the second naturally occurring cleavage during normal HCV infection.
5. (Previously presented) The immunogenic composition of claim 3, wherein the truncated Core protein has a deletion of at least the C-terminal 10 amino acids.
6. (Previously presented) The immunogenic composition of claim 3, wherein the truncated Core protein consists of sequence encoding amino acids 1-151 of the Core protein.

7. (Withdrawn) The immunogenic composition of claim 3, wherein the truncated core protein consists of sequence encoding amino acids 1-165 of the Core protein.
8. (Withdrawn) The immunogenic composition of claim 1, wherein the second expression cassette encodes NS5B protein.
9. (Previously presented) The immunogenic composition of claim 8, wherein the first expression cassette encodes the Core protein in fusion with the HCV NS3 protein.
10. (Previously presented) The immunogenic composition of claim 8, wherein the first expression cassette encodes a double fusion protein NS3-Core and the second expression cassette encodes a NS4B-NS5B double fusion protein.
11. (Previously presented) The immunogenic composition of claim 10, wherein the Core element of the NS3-Core double fusion protein is selected from the group consisting of sequence encoding: amino acids 1-171 of the Core protein, amino acids 1-165 of the Core protein, and amino acids 1-151 of the Core protein.
12. (Withdrawn) The immunogenic composition of claim 11, wherein the Core element of the NS3-Core double fusion protein is sequence encoding amino acids 1-165 of the Core protein.
13. (Withdrawn) The immunogenic composition of claim 1, wherein the at least one other HCV protein comprises sequence encoding an HCV protein selected from the group of: NS3, NS4B and NS5B.
14. (Cancelled)
15. (Previously presented) The immunogenic composition of claim 1, wherein the polynucleotide sequence is a plasmid.
16. (Previously presented) The immunogenic composition of claim 1, wherein the polynucleotides are codon optimised for expression in mammalian cells.
17. (Previously presented) The immunogenic composition of claim 2, wherein the mutation reduces expression of the Core protein upon the expression of said at least one other HCV protein, wherein the Core protein encoded by the polynucleotide vaccine

Attorney Docket No VB60547  
Serial No 10/534,774  
Group Art No 1648

consists of one of the following group of sequences encoding: amino acids 1-151 of the Core protein, amino acids 1-165 of the Core protein, and amino acids 1-171 of the Core protein.

18. (Withdrawn) A method of preventing or treating an HCV infection in a mammal comprising administering a vaccine as claimed in claim 1 to a mammal.

19. (Withdrawn) A method of vaccinating an individual comprising taking a polynucleotide vaccine as claimed in claim 1, coating the gold beads with the polynucleotide vaccine and delivering the gold beads into the skin.

20. (Cancelled)